以腹痛、腹泻首诊合并腹膜后脓肿的甲状腺髓样癌1例
|
摘要
<正>甲状腺髓样癌(medullary thyroid carcinoma,MTC)是起源于甲状腺滤泡旁细胞的内分泌恶性肿瘤,其恶性程度较高,预后差,我院近期收治1例以腹痛、腹泻为首发症状同时合并腹膜后脓肿的MTC,现报道如下。1临床资料患者女,55岁,因"间断腹痛伴腹泻2月余"入
引文
[1]Wells SA Jr,Asa SL,Dralle H,et al.Revised american thyroid association guidelines for the management of medullary thyroid carcinoma[J].Thyroid,2015,25(6):567-610.
[2]Romei C,Casella F,Tacito A,et al.New insights in the molecular signature of advanced medullary thyroid cancer:evidence of a bad outcome of cases with double RET mutations[J].J Med Genet,2016,53(11):729-734.
[3]Schneider DF,Chen H.New developments in the diagnosis and treatment of thyroid cancer[J].CA Cancer J Clin,2013,63(6):374-394.
[4]Jin LX,Moley JF.Surgery for lymph node metastases of medullary thyroid carcinoma:a review[J].Cancer,2016,122(3):358-366.
[5]陈晓红.甲状腺髓样癌指南变迁与我国目前面临任务[J].国际耳鼻咽喉头颈外科杂志,2018,42(1):53-56.
[6]薛声能,雷娟,李娜,等.降钙素和癌胚抗原联合检测在甲状腺髓样癌诊治中的意义[J].中国卫生检验杂志,2012,22(7):1620-1621,1624.
[7]殷德涛,张高朋,李红强,等.甲状腺结节患者常规行血清降钙素检查对早期发现甲状腺髓样癌的临床价值[J].中国普通外科杂志,2018,27(5):541-546.
[8]Milone F,Ramundo V,Chiofalo MG,et al.Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels[J].Clin Endocrinol(Oxf),2010,73(1):85-88.
[9]Kwon H,Kim WG,Choi YM,et al.A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma[J].Clin Endocrinol(Oxf),2015,82(4):598-603.
[10]Allelein S,Ehlers M,Morneau C,et al.Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J].Horm Metab Res,2018,50(1):23-28.
[11]Machens A,Hoffmann F,Sekulla C,et al.Importance of genderspecific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer[J].Endocr Relat Cancer,2009,16(4):1291-1298.
[12]龚艳萍,刘枫,邹秀和,等.甲状腺髓样癌的诊治进展[J].中国普外基础与临床杂志,2016,23(5):620-625.
[13]张刚.遗传性甲状腺髓样癌MEN2A家系的临床诊治分析[D].第三军医大学,2016.
[14]Takeuchi S,Shiga T,Hirata K,et al.Early prediction of lenvatinib treatment efficacy by using F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment:a protocol for a non-randomized single-arm multicenter observational study[J].BMJ Open,2018,8(8):e021001.
[15]Miyauchi A,Matsuzuka F,Hirai K,et al.Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations[J].World J Surg,2002,26(8):1023-1028.
[16]Sun Y,Du F,Gao M,et al.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J].Thyroid,2018,24[Epub ahead of print].
[2]Romei C,Casella F,Tacito A,et al.New insights in the molecular signature of advanced medullary thyroid cancer:evidence of a bad outcome of cases with double RET mutations[J].J Med Genet,2016,53(11):729-734.
[3]Schneider DF,Chen H.New developments in the diagnosis and treatment of thyroid cancer[J].CA Cancer J Clin,2013,63(6):374-394.
[4]Jin LX,Moley JF.Surgery for lymph node metastases of medullary thyroid carcinoma:a review[J].Cancer,2016,122(3):358-366.
[5]陈晓红.甲状腺髓样癌指南变迁与我国目前面临任务[J].国际耳鼻咽喉头颈外科杂志,2018,42(1):53-56.
[6]薛声能,雷娟,李娜,等.降钙素和癌胚抗原联合检测在甲状腺髓样癌诊治中的意义[J].中国卫生检验杂志,2012,22(7):1620-1621,1624.
[7]殷德涛,张高朋,李红强,等.甲状腺结节患者常规行血清降钙素检查对早期发现甲状腺髓样癌的临床价值[J].中国普通外科杂志,2018,27(5):541-546.
[8]Milone F,Ramundo V,Chiofalo MG,et al.Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels[J].Clin Endocrinol(Oxf),2010,73(1):85-88.
[9]Kwon H,Kim WG,Choi YM,et al.A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma[J].Clin Endocrinol(Oxf),2015,82(4):598-603.
[10]Allelein S,Ehlers M,Morneau C,et al.Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J].Horm Metab Res,2018,50(1):23-28.
[11]Machens A,Hoffmann F,Sekulla C,et al.Importance of genderspecific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer[J].Endocr Relat Cancer,2009,16(4):1291-1298.
[12]龚艳萍,刘枫,邹秀和,等.甲状腺髓样癌的诊治进展[J].中国普外基础与临床杂志,2016,23(5):620-625.
[13]张刚.遗传性甲状腺髓样癌MEN2A家系的临床诊治分析[D].第三军医大学,2016.
[14]Takeuchi S,Shiga T,Hirata K,et al.Early prediction of lenvatinib treatment efficacy by using F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment:a protocol for a non-randomized single-arm multicenter observational study[J].BMJ Open,2018,8(8):e021001.
[15]Miyauchi A,Matsuzuka F,Hirai K,et al.Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations[J].World J Surg,2002,26(8):1023-1028.
[16]Sun Y,Du F,Gao M,et al.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J].Thyroid,2018,24[Epub ahead of print].